SOFINNOVA-PARTNERS
14.10.2020 08:02:10 CEST | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Dr. Joe Anderson as Partner in the Sofinnova Crossover Fund, effective immediately.
Dr. Anderson has over 25 years’ experience in the healthcare and life sciences industries. Previously, he was a Partner at Abingworth LLP for over a decade, where he led venture-style investments in public companies and the formation of the firm’s public equities fund. Most recently, Dr. Anderson was Co-Founder and Chief Executive Officer at Arix Bioscience plc, a venture capital firm listed on the London Stock Exchange.
Dr. Anderson has substantial experience as an active Board Member developing innovative life sciences companies in the UK and the US and his investments have involved numerous private and public financing rounds, IPOs, M&As and exits.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “Joe’s arrival signals a decisive moment of growth for the Sofinnova Crossover Fund. It comes on the heels of a number of recent milestones, including two IPOs on the Nasdaq, new investments, positive clinical data and key appointments in our portfolio companies. His extensive experience leading venture capital investments in private and public companies will allow us to continue building on the great work of the Crossover team and positions Sofinnova Partners for further expansion.”
Joe Anderson commented: “I am delighted to join Sofinnova Partners at this exciting time for life sciences in Europe. The firm has been a pioneer in life sciences investing, most recently through the founding of the Sofinnova Crossover Fund -- one of the first of its kind in Europe. Record numbers of companies are being formed from a flourishing science base in Europe. Access to later-stage scale-up capital is crucial as they seek to build and retain value and the need for this kind of investment has never been greater. I look forward to working with my colleagues to further develop this leading European strategy.”
Jacques Theurillat, Partner in the Sofinnova Crossover Fund, commented: “We warmly welcome Joe to the Sofinnova Crossover team. Joe’s knowledge and expertise will further reinforce our experienced team of investment partners, Kinam Hong, Cédric Moreau, Tom Burt and myself, as we support ground-breaking innovations and enable later-stage life sciences companies to reach their full potential.”
Dr. Anderson began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became Head of the strategy group. He then moved to the City as a pharmaceuticals analyst at Dresdner Kleinwort Benson, before being appointed Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. He then joined Abingworth LLP as a Partner for 12 years before moving on to co-found Arix Biosciences in 2016 and lead its IPO on the London Stock Exchange the following year. He holds a Ph.D. in Biochemistry.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005998/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 14:00:00 CEST | Press release
Bridging digital assets, traditional finance, enterprise treasury, and agentic commerce through global programmable money infrastructure Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded
Esri Sponsors Smithsonian Exhibition Showcasing Natural and Cultural Objects from All 50 States29.6.2026 14:00:00 CEST | Press release
From These Lands Exhibition Highlights Connections Between People, Place, and Natural World Through Physical Specimens and Digital Maps Esri is the lead sponsor of the Smithsonian's From These Lands exhibition and developed maps powered by ArcGIS and a digital companion to extend engagement beyond the museum. The exhibition features more than 600 specimens and cultural artifacts from all 50 states, Washington, DC, and US territories, drawn from the Smithsonian's National Museum of Natural History's collection of over 148 million objects. Designed around themes of connection, diversity, and discovery, the exhibit explores how landscapes, ecosystems, and cultural traditions shape one another across regions and time. Animated mapping experiences enable visitors to explore topography, biomes, geology, migration patterns, and watersheds, revealing relationships across the continent. ArcGIS StoryMaps transforms the physical exhibit into an accessible digital narrative, extending its reach to
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station29.6.2026 14:00:00 CEST | Press release
UC Irvine researchers use single cell RNA sequencing to study cartilage tissue engineered in microgravity Researchers in the DELTAi Lab at the University of California, Irvine, working with NASA, are using Evercode Cell Fixation to preserve samples aboard the International Space Station as part of a study of cartilage tissue engineering in microgravity. The unprecedented work, part of a National Science Foundation (NSF)-funded grant led by Dr. Wendy Brown and Dr. Kyriacos Athanasiou, announced today by Parse Biosciences, aims to advance treatments for the hundreds of millions of people worldwide affected by cartilage injury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629548658/en/ Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes into orbit. Cartilage injuries cause significant pain and disability, and the need for implants that can repair or regenerate damaged tissue
Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour29.6.2026 13:55:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315) today announced that it has received a first-instance civil judgment from the Shanghai Intellectual Property Court. The court ruled that Biocytogen did not infringe the relevant patent rights asserted by the plaintiff, Harbour Antibodies BV ("Harbour"), and ordered the plaintiff to bear the litigation costs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/ Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour The judgment marks a significant first-instance outcome in the litigation and further affirms the independent innovation and intellectual property compliance of Biocytogen's core technology platforms. It also provides greater clarity for existing and prospective partners evaluating the RenNano® platform, reinforcing confidence in the Company's technology platforms and long-term innovation capabi
MANE Selects Kinaxis to Strengthen Global Planning Capabilities29.6.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to provide the digital foundation to strengthen MANE’s global planning capabilities and support its continued planning transformation Kinaxis®(TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that MANE, one of the top five leading organizations worldwide in the flavours and fragrances industry, has selected Kinaxis to modernize its planning capabilities as it accelerates global growth as part of a broader enterprise-wide transformation initiative. Headquartered in the south of France, with a significant global footprint spanning multiple regions and customers across international markets, MANE is known for its innovation, technical expertise and strong commitment to sustainability. The company is investing in more connected, end-to-end planning capabilities to support continued growth and increasing operational complexity worldwide. Following an extensive evaluation process with major competitors in the market, M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom